Israeli Medical device startup Filterlex closes $6m Series A1 investment to accelerate CAPTIS cardiovascular clinical program
Filterlex Medical, a cardiovascular medical device startup, announced it completed a $6 million series A1 investment round from private healthcare investors. The financing will accelerate implementation of the company's CAPTIS® clinical program. The CAPTIS is a next-generation, full-body embolic protection device to reduce the risk of stroke and other complications during left-heart procedures.
Sigal Eli, Founder and CEO, Filterlex Medical: "We are excited by the rapid closing of the new round of funding. With the excellent progress in our clinical program and the recent move to our larger facility in Caesarea, we are well positioned to deliver our vision of making the CAPTIS a best-in-class device."
During catheter-based procedures, such as Transcatheter Aortic Valve Replacement (TAVR), embolic particles are often released into the blood flow and may cause neurological deficiencies, from cognitive impairment to debilitating stroke. As demonstrated in our first-in-human study, the CAPTIS device is easily and intuitively deployed and retrieved. It is securely positioned in the aorta, protecting its surface, while facilitating a seamless TAVR procedure. The CAPTIS uniquely requires no additional arterial access and does not interfere with the procedure workflow.
The financing will accelerate implementation of the Company's clinical program. The CAPTIS first-in-human study is successfully ongoing and actively enrolling patients in two leading centers in Israel, Wolfson Medical Center and Rabin Medical Center (Beilinson Hospital).
Haim Danenberg, the study principal investigator and Head of Interventional Cardiology at the Wolfson Medical Center said, "We are thrilled with the opportunity to use the CAPTIS device to protect our TAVR patients' brain and kidneys." Prof. Ran Kornowski, Director of the Cardiology Center at Rabin Medical Center, added, "Our initial experience with the CAPTIS is very positive. The system is safe, intuitive, and easy to use."